Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a selective 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a 5‑HT3 receptor antagonist indicated for several chemotherapy‑related indications. - Chemotherapy‑induced nausea and vomiting (CINV): provides effective prophylaxis of acute and delayed episodes in adult patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: helps control nausea associated with moderate to high dose radiotherapy. - Antiemesis in patients receiving moderately emetogenic chemotherapy: offers prophylaxis when lower‑risk regimens are used.

Palonosetron may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Fatigue: general tiredness without specific cause. - Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: QT‑interval prolongation in susceptible patients. - Severe constipation or intestinal obstruction. - Serotonin syndrome: rare when combined with other serotonergic agents.

When using Palonosetron Fresenius Kabi, clinicians should consider several safety aspects. - Cardiac monitoring: assess QT interval in patients with known cardiac risk factors. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome. - Renal or hepatic impairment: adjust monitoring as drug clearance may be affected. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Allergy history: verify no prior hypersensitivity to palonosetron or other 5‑HT3 antagonists. - Store at ambient temperature: keep in original container, protect from light and moisture.

Palonosetron can interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - QT‑prolonging agents: concurrent use may increase risk of serious cardiac arrhythmias. - Strong CYP3A4 inhibitors: may raise palonosetron plasma concentrations.

Moderate Interactions (Monitor Closely): - Other serotonergic drugs (e.g., SSRIs, tramadol): monitor for serotonin syndrome. - Anticholinergic agents: may exacerbate constipation. - Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.